Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1363084

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1363084

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Colorectal Cancer Therapeutics Market Growth & Trends:

The global colorectal cancer therapeutics market size is expected to reach USD 16.7 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.7% from 2023 to 2030. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Colorectal Cancer Therapeutics Market Report Highlights:

  • Immunotherapy dominated the market based on drug class in 2022, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
  • Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
  • U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
  • Roche led the colorectal cancer industrial setting in 2022 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2022. However, Roche is projected to lose market share on grounds of Avastin's patent expiry and biosimilar penetration
  • Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.
Show more
Product Code: GVR-2-68038-512-0

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug class
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Colorectal Cancer Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Colorectal Cancer Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Colorectal Cancer Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Colorectal Cancer Therapeutics Market: Key Takeaways
  • 4.2. Colorectal Cancer Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Colorectal Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Colorectal Cancer Therapeutics Market by Region: Key Takeaway
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Amgen, Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bayer AG
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Bristol-Myers Squibb Company
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Lilly
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Merck & co., Inc.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Sanofi
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
Show more
Product Code: GVR-2-68038-512-0

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Canada colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Europe colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Europe colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 UK colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 France colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Italy colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Spain colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Sweden colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Norway colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Denmark colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 China colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 India colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Australia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Thailand colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 South Korea colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Latin America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Latin America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Mexico colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Argentina colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 UAE colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Kuwait colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Colorectal cancer therapeutics: Market outlook
  • Fig. 9 Colorectal cancer therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Colorectal cancer therapeutics market driver impact
  • Fig. 15 Colorectal cancer therapeutics market restraint impact
  • Fig. 16 Colorectal cancer Therapeutics market strategic Initiatives analysis
  • Fig. 17 Colorectal cancer therapeutics market: Drug class movement analysis
  • Fig. 18 Colorectal cancer therapeutics market: Drug class outlook and key takeaways
  • Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global Colorectal Cancer Therapeutics market: Regional Movement Analysis
  • Fig. 23 Global Colorectal cancer therapeutics market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!